MAIA Biotechnology Inc.(MAIA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MAIA MAIA Biotechnology Inc.

未开盘 10-21 16:00:00 EDT

1.14

+0.02

+1.79%

盘后1.12

-0.02-1.75%

19:59 EDT

最高1.15	最低1.06	成交量10.79万
今开1.13	昨收1.12	日振幅8.04%
总市值7,039万	流通市值6,304万	总股本6,174万
成交额12.24万	换手率0.20%	流通股本5,530万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MAIA","market":"US","secType":"STK","nameCN":"MAIA Biotechnology Inc.","latestPrice":1.14,"timestamp":1792612800000,"preClose":1.12,"halted":0,"volume":107870,"hourTrading":{"tag":"盘后","latestPrice":1.12,"preClose":1.14,"latestTime":"19:59 EDT","volume":672,"amount":759.85,"timestamp":1792627150055,"change":-0.02,"changeRate":-0.017544,"amplitude":0.026316},"delay":0,"changeRate":0.017857142857142672,"floatShares":55296811,"shares":61741899,"eps":-0.608478,"marketStatus":"未开盘","change":0.02,"latestTime":"10-21 16:00:00 EDT","open":1.13,"high":1.15,"low":1.06,"amount":122398.70826399999,"amplitude":0.080357,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.608478,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1792656000000},"marketStatusCode":0,"adr":0,"listingDate":1659067200000,"exchange":"AMEX","adjPreClose":1.12,"preHourTrading":{"tag":"盘前","latestPrice":1.1202,"preClose":1.12,"latestTime":"09:02 EDT","volume":412,"amount":461.99562319999995,"timestamp":1792587751042,"change":0.0002,"changeRate":0.000179,"amplitude":0.01625},"postHourTrading":{"tag":"盘后","latestPrice":1.12,"preClose":1.14,"latestTime":"19:59 EDT","volume":672,"amount":759.85,"timestamp":1792627150055,"change":-0.02,"changeRate":-0.017544,"amplitude":0.026316},"volumeRatio":0.237303},"requestUrl":"/m/hq/s/MAIA/tweets","defaultTab":"tweets","newsList":[{"id":"1123603494","title":"MAIA Biotechnology公布晚期非小细胞肺癌关键性III期临床试验进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1123603494","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123603494?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:48","pubTimestamp":1790081290,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology Inc.今日宣布，其在晚期非小细胞肺癌领域的关键性III期临床试验已取得阶段性进展。这一里程碑式的成果，为该公司在肿瘤免疫治疗赛道的战略布局注入了强劲动力。值得注意的是，该试验旨在评估其核心候选药物的疗效与安全性，数据初步显示出令人鼓舞的信号，有望为这一难治性患者群体开辟新的治疗路径。公司管理层强调，后续将加速推进数据收集与分析工作，并计划在近期召开的学术会议上披露更详尽的临床结果。市场分析人士指出，此番进展不仅强化了MAIA的研发管线价值，也可能重塑其在精准医疗领域的竞争格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140435594","title":"Maia Biotechnology在持续进行的非小细胞肺癌二期临床试验中完成首例美国患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1140435594","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140435594?lang=zh_cn&edition=full","pubTime":"2026-09-16 20:15","pubTimestamp":1789560912,"startTime":"0","endTime":"0","summary":"Maia Biotechnology于正在推进的非小细胞肺癌二期临床试验中，已完成对美国首位患者的药物剂量给药。这一里程碑式进展标志着该试验在美国境内正式启动患者入组阶段。此次临床研究的推进，为Maia Biotechnology在肺癌治疗领域的管线开发注入了新的动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179023415","title":"Maia Biotechnology长期董事会成员与CEO相继增持公司股票","url":"https://stock-news.laohu8.com/highlight/detail?id=1179023415","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179023415?lang=zh_cn&edition=full","pubTime":"2026-09-15 20:21","pubTimestamp":1789474894,"startTime":"0","endTime":"0","summary":"Maia Biotechnology宣布，公司一位长期任职的董事会成员及首席执行官已在公开市场上购入公司股票。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658042939","title":"据The Information：微软计划于9月发布其下一代MAIA 300人工智能芯片。","url":"https://stock-news.laohu8.com/highlight/detail?id=2658042939","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658042939?lang=zh_cn&edition=full","pubTime":"2026-08-10 21:02","pubTimestamp":1786366922,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ARMG","TSMX","TWSC","GFSG","SEMI","NVDX","TSMZ","AMUU","AIYY","MAIA","XIGV","TCHI","TSMY","NVIT","SHOC","ARMA","MSFT","NVDU","AMDG","FTEC","NYYY","SMHC","INT","AMDY","ONG","CHPX","AMDD","ARMH","SEMY","IYW","SPTE","SOXM","TSMG","NVDK","MUU","INYY","TSXU","NVDG","AMDL","NVDW","XSEM","AMDC","SOXW","NVC","QQQM","NVDL","TSXD","BCTK","IXN","AVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171617541","title":"MAIA Biotechnology宣布：Ateganosine联合Cemiplimab在3L NSCLC中疾病控制率优于标准化疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1171617541","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171617541?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:50","pubTimestamp":1783522245,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology Inc. 公布了其THIO-101研究C部分扩展试验的初步疗效数据，该试验针对三线治疗的非小细胞肺癌患者。数据显示，药物Ateganosine联合Cemiplimab在经大量前期治疗的患者中展现出可接受的安全性。\n尤为引人注目的是，在该试验中，联合疗法取得了90.5%的疾病控制率。这一结果显著优于当前三线非小细胞肺癌治疗中标准化疗方案所达到的疾病控制率水平。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174196104","title":"MAIA Biotechnology公布Thio-101二期C部分扩展试验在三线非小细胞肺癌中的强劲初步疗效数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1174196104","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174196104?lang=zh_cn&edition=full","pubTime":"2026-07-08 21:49","pubTimestamp":1783518572,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology公布了其Thio-101二期临床试验C部分扩展研究的最新结果，该研究针对三线治疗的非小细胞肺癌患者。数据显示了积极的初步疗效信号，为这款候选药物的开发前景注入了新的动力。这一进展有望为晚期肺癌患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195875612","title":"MAIA Biotechnology联合治疗方案在经多重治疗患者中展现可接受的安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=1195875612","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195875612?lang=zh_cn&edition=full","pubTime":"2026-07-08 21:47","pubTimestamp":1783518441,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology Inc. 公布的数据显示，其候选药物阿特甘诺辛与西米普利单抗的联合疗法，在先前已接受过大量治疗的晚期实体瘤患者群体中，展现出了可接受的安全性特征。\n该组合疗法的初步安全性评估结果积极，未出现超出预期的严重不良反应。这对于那些治疗选择有限的经多重治疗患者而言，是一个重要的临床进展。公司将继续推进相关临床研究，以进一步评估该联合疗法的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649098999","title":"MAIA BIOTECHNOLOGY - ATEGANOSINE联合CEMIPLIMAB在经多线治疗患者中显示出可接受的","url":"https://stock-news.laohu8.com/highlight/detail?id=2649098999","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649098999?lang=zh_cn&edition=full","pubTime":"2026-07-08 21:45","pubTimestamp":1783518345,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150530335","title":"MAIA Biotechnology完成THIO-101二期扩展试验C部分国际患者入组，针对三线非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1150530335","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150530335?lang=zh_cn&edition=full","pubTime":"2026-06-25 20:08","pubTimestamp":1782389297,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc. (简称: MAIA) 已成功完成其THIO-101二期扩展试验C部分的国际患者入组工作。该试验旨在评估其在研疗法对三线非小细胞肺癌（NSCLC）患者的疗效与安全性。\n此项进展标志着MAIA在推进其创新肿瘤疗法临床开发过程中的重要一步。THIO-101试验的C部分专注于国际多中心研究，其完成将有助于加速数据收集，并为后续临床决策提供关键依据。公司致力于解决晚期非小细胞肺癌领域未被满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149934769","title":"MAIA Biotechnology启动新型端粒靶向药物二期扩展试验患者招募，合作机构为埃默里大学Winship癌症研究所","url":"https://stock-news.laohu8.com/highlight/detail?id=1149934769","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149934769?lang=zh_cn&edition=full","pubTime":"2026-06-18 20:31","pubTimestamp":1781785882,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology公司宣布，已启动其新型端粒靶向药物二期临床试验扩展阶段的患者招募工作。此项试验将在埃默里大学Winship癌症研究所进行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642238041","title":"Compugen将展示MAIA-卵巢癌药物试验最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2642238041","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642238041?lang=zh_cn&edition=full","pubTime":"2026-06-11 23:18","pubTimestamp":1781191080,"startTime":"0","endTime":"0","summary":"以色列临床阶段癌症免疫疗法公司Compugen Ltd．周四宣布，将在2026年欧洲肿瘤内科学会妇科癌症大会上以壁报形式展示其MAIA-卵巢试验的最新进展。该大会将于6月17日至19日在丹麦哥本哈根举行。　　此次展示的壁报将重点介绍COM701在复发性铂敏感卵巢癌患者中作为维持治疗的安全性和有效性。Compugen总裁兼首席执行官表示，随着MAIA-卵巢试验所有临床站点持续推进患者入组，公司仍按计划在2027年第一季度进行期中分析，这可能是COM701作为维持疗法的一个重要转折点。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-11/doc-inicaeni3872861.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118694640","title":"MAIA Biotechnology启动并开放美国第二临床中心，为国际二期Thio-101扩展试验招募患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1118694640","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118694640?lang=zh_cn&edition=full","pubTime":"2026-06-10 21:18","pubTimestamp":1781097510,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology已启动其在美国的第二处临床研究中心，并正式开放患者招募，以推进其国际二期Thio-101扩展试验的开展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175970869","title":"MAIA Biotechnology宣布非小细胞肺癌关键三期试验入组与给药势头强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=1175970869","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175970869?lang=zh_cn&edition=full","pubTime":"2026-06-04 21:45","pubTimestamp":1780580755,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology Inc. (MAIA) 宣布，其针对非小细胞肺癌的关键性三期临床试验在患者入组和给药方面展现出强劲势头。这项重要试验的积极进展，标志着公司在推进其癌症疗法开发方面取得了实质性进展，为后续的数据读出和潜在监管提交奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190175702","title":"MAIA Biotechnology获FDA批准在美国开启Thio-101二期试验扩展阶段患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1190175702","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190175702?lang=zh_cn&edition=full","pubTime":"2026-06-03 21:45","pubTimestamp":1780494348,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology公司已获得美国食品药品监督管理局（FDA）的许可，将开始在美国招募患者，以推进其正在进行的Thio-101二期临床试验的扩展阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155537652","title":"MAIA Biotechnology 在2026年美国临床肿瘤学会年会上展示其新型端粒靶向药物关键性III期临床试验的进行中试验海报","url":"https://stock-news.laohu8.com/highlight/detail?id=1155537652","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155537652?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:01","pubTimestamp":1780315314,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology Inc. 在2026年美国临床肿瘤学会年会上，展示了其关于新型端粒靶向药物关键性III期临床试验的“试验进行中”海报。该海报详细介绍了这项旨在评估药物疗效与安全性的关键研究的设计与当前进展。此次展示标志着该公司核心候选药物研发进程中的一个重要节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158612694","title":"MAIA Biotechnology Inc. 根据销售协议出售310万股，总收益达570万美元 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1158612694","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158612694?lang=zh_cn&edition=full","pubTime":"2026-05-15 05:06","pubTimestamp":1778792813,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology Inc. 已根据一份销售协议，成功出售了310万股普通股，获得总收益约570万美元。此举旨在为公司运营提供额外资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150846959","title":"MAIA Biotechnology Inc. 将于2026年5月23日起终止市场发行协议 - 美国证券交易委员会文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1150846959","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150846959?lang=zh_cn&edition=full","pubTime":"2026-05-15 05:05","pubTimestamp":1778792750,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology Inc. 已提交文件，宣布其市场发行协议将于2026年5月23日起正式终止。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518094372","title":"Maia Biotechnology, Inc.盘中异动 下午盘急速跳水5.36%报1.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518094372","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518094372?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:31","pubTimestamp":1741631474,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时31分，Maia Biotechnology, Inc.股票出现波动，股价大幅下挫5.36%。截至发稿，该股报1.56美元/股，成交量5.4463万股，换手率0.19%，振幅6.67%。Maia Biotechnology, Inc.股票所在的生物技术行业中，整体涨幅为0.64%。其相关个股中，Mineralys Therapeutics, Inc.、Aeon Biopharma, Inc.、Checkpoint Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.较为活跃，换手率分别为6034.69%、3847.62%、1006.90%，振幅较大的相关个股有Aeon Biopharma, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Biodexa Pharmaceuticals Plc，振幅分别为90.44%、88.14%、59.34%。Maia Biotechnology, Inc.公司简介：MAIA Biotechnology Inc 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311023114a26a935d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311023114a26a935d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517116675","title":"Maia Biotechnology, Inc.盘中异动 早盘股价大跌5.38%报1.58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517116675","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517116675?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:34","pubTimestamp":1741271645,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时34分，Maia Biotechnology, Inc.股票出现波动，股价急速下挫5.38%。Maia Biotechnology, Inc.股票所在的生物技术行业中，整体跌幅为0.64%。其相关个股中，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Coeptis Therapeutics Holdings Inc C/Wts 28/10/2027 涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为982.88%、121.32%、51.43%，振幅较大的相关个股有Plus Therapeutics, Inc.、Coeptis Therapeutics Holdings Inc C/Wts 28/10/2027 、Aeon Biopharma, Inc.，振幅分别为24.20%、23.12%、21.05%。Maia Biotechnology, Inc.公司简介：MAIA Biotechnology Inc 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223406963c4d52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223406963c4d52&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516546256","title":"Maia Biotechnology, Inc.盘中异动 急速下跌5.88%报1.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516546256","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516546256?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:22","pubTimestamp":1741026178,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时22分，Maia Biotechnology, Inc.股票出现异动，股价急速下挫5.88%。截至发稿，该股报1.77美元/股，成交量7.9285万股，换手率0.30%，振幅4.23%。Maia Biotechnology, Inc.股票所在的生物技术行业中，整体涨幅为0.15%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Radiopharm Theranostics Limited涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4374.50%、190.80%、179.20%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Maia Biotechnology, Inc.公司简介：MAIA Biotechnology Inc 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304022259abe67676&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304022259abe67676&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.MAIABiotech.com","stockEarnings":[{"period":"1week","weight":0.0179},{"period":"1month","weight":-0.1429},{"period":"3month","weight":-0.1094},{"period":"6month","weight":-0.1024},{"period":"1year","weight":-0.1618},{"period":"ytd","weight":-0.2549}],"compareEarnings":[{"period":"1week","weight":0.0045},{"period":"1month","weight":-0.0005},{"period":"3month","weight":0.0473},{"period":"6month","weight":0.0829},{"period":"1year","weight":0.1516},{"period":"ytd","weight":0.1337}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"MAIA Biotechnology, Inc.于2018年8月3日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，开发针对癌症的靶向免疫疗法。该公司的主要资产THIO是一种研究性双重作用机制的候选药物，结合了端粒靶向和免疫原性。THIO是一种端粒靶向剂，目前正在临床开发中以评估其在NSCLC中的活性。THIO正被开发为NSCLC的二线或后续治疗线，用于治疗进展超过现有检查点抑制剂标准治疗方案的患者。公司THIO项目带动了公司第二代端粒靶向剂的开发管线。该公司已经启动了一项早期研究和发现计划，旨在确定能够通过与THIO类似的活性机制发挥作用的新化合物，例如通过癌细胞固有的端粒酶活性靶向和修饰癌细胞的端粒结构。该公司目前的第二代潜在端粒靶向剂管道包括五种化合物，这些化合物已在五种癌症模型中成功进行了体外抑制测试。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.285723},{"month":2,"riseRate":0,"avgChangeRate":-0.06082},{"month":3,"riseRate":0.25,"avgChangeRate":-0.026788},{"month":4,"riseRate":0.5,"avgChangeRate":0.130553},{"month":5,"riseRate":0.75,"avgChangeRate":0.111873},{"month":6,"riseRate":0.5,"avgChangeRate":-0.089611},{"month":7,"riseRate":0.25,"avgChangeRate":-0.076547},{"month":8,"riseRate":0.2,"avgChangeRate":-0.109363},{"month":9,"riseRate":0.2,"avgChangeRate":-0.019779},{"month":10,"riseRate":0.2,"avgChangeRate":-0.038482},{"month":11,"riseRate":0.25,"avgChangeRate":-0.189158},{"month":12,"riseRate":0.5,"avgChangeRate":0.077797}],"exchange":"AMEX","name":"MAIA Biotechnology Inc.","nameEN":"MAIA Biotechnology Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MAIA Biotechnology Inc.(MAIA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供MAIA Biotechnology Inc.(MAIA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"MAIA Biotechnology Inc.,MAIA,MAIA Biotechnology Inc.股票,MAIA Biotechnology Inc.股票老虎,MAIA Biotechnology Inc.股票老虎国际,MAIA Biotechnology Inc.行情,MAIA Biotechnology Inc.股票行情,MAIA Biotechnology Inc.股价,MAIA Biotechnology Inc.股市,MAIA Biotechnology Inc.股票价格,MAIA Biotechnology Inc.股票交易,MAIA Biotechnology Inc.股票购买,MAIA Biotechnology Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MAIA Biotechnology Inc.(MAIA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供MAIA Biotechnology Inc.(MAIA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}